Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock

LOS ANGELES, CA, Feb. 08, 2024 -- Immix Biopharma, Inc. , a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, announced today the closing of...

Related Keywords

United States ,New York ,American ,Mike Moyer ,Titan Partners Group ,Exchange Commission ,Company Contact ,Immix Biopharma Inc ,American Capital Partners ,World Trade Center ,Partners Group ,Trade Center ,Immix Biopharma ,Securities Litigation Reform Act ,